We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Bmp8.0
Bimatoprost (lashes) Research
Mostly mechanism / observationalLimited safety
8 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Bimatoprost (lashes) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality meta-analyses and randomised trials published 2009–2023 with a typical study size of 209 participants.
Based on 8 studies · 2 meta-analyses · 3 RCTs · 1,269 total participants
Confidence
High
By outcome
Hair & nails
Mostly mechanism / observational7 studies
Safety profile
Mostly mechanism / observational4 studies
Steady research
1 study in the last 5 years · Latest meta-analysis: 2023
200920162023
1RCT2015
The primary efficacy end point was met in both populations (idiopathic responder rate was 40.2% for bimatoprost vs. 6.8% for vehicle; postchemotherapy responder rate was 37.5% for bimatoprost vs. 18.2% for vehicle).
Glaser DA, Hossain P, Perkins W, Griffiths T, Ahluwalia G, Weng E, Beddingfield FC. · Br J Dermatol (2015)
1-year double-masked RCT: composite primary endpoint (Global Eyelash Assessment + satisfaction) met for bimatoprost vs vehicle in idiopathic (40.2% vs 6.8%) and post-chemotherapy (37.5% vs 18.2%) hypotrichosis
Efficacy maintained or enhanced through 12 months of daily use
Not durable: effects maintained ~2 months but markedly diminished 4-6 months after cessation — continuous use needed
The results showed that prostaglandin analogs could significantly improve the hair length and density (p < 0.001). As far as adverse events are concerned, there was no significant difference between the experimental group and the control group.
Jiang S, Hao Z, Qi W, Wang Z, Zhou M, Guo N. · Front Med (Lausanne) (2023)
Meta-analysis of six placebo-controlled RCTs of topical prostaglandin analogs (incl. bimatoprost) for hair growth (lashes, brows, scalp)
Significantly improved hair length and density vs placebo (p<0.001), with no significant difference in adverse-event rates
Authors note the optimal dose and frequency still require further study
Significantly more bimatoprost-treated subjects had at least a one-grade improvement in GEA score from baseline to month 4 compared with vehicle in study 1 (77.3 vs 17.6%; P<0.001) and study 2 (88.9 vs 27.8%; P<0.001).
Harii K, Arase S, Tsuboi R, Weng E, Daniels S, VanDenburgh A. · Aesthetic Plast Surg (2014)
Two double-masked vehicle-controlled RCTs (n=209: 173 idiopathic, 36 chemotherapy-induced) in Japanese subjects
Far more bimatoprost subjects achieved ≥1-grade GEA improvement at month 4 (77.3% vs 17.6%; 88.9% vs 27.8%)
Digital image analysis confirmed greater increases in lash length, thickness, and darkness; adverse events similar to vehicle
Most adverse events occurred early in treatment, were mild in intensity, localized to treatment site, and reversible with treatment cessation. Discontinuations due to adverse events were low (3.2% for bimatoprost and 2.4% for vehicle).
Wirta D, Pariser DM, Yoelin SG, Arase S, McMichael A, Weng E, Mao C, Demos G, Vandenburgh A. · J Clin Aesthet Dermatol (2015)
Pooled safety data from six randomized double-masked trials (n=1059: 680 bimatoprost, 379 vehicle)
Most were mild, localized, early, and reversible; discontinuations were low (3.2% vs 2.4%)
5Review2018
Its proposed mechanism is stimulation of the prostaglandin receptor in dermal papilla and melanocyte, thus leading to a prolonged anagen phase and increased melanogenesis. The hair follicle then increases in thickness, length, and darkness.
Chanasumon N, Sriphojanart T, Suchonwanit P. · Drug Des Devel Ther (2018)
Reviews bimatoprost's mechanism: prostaglandin-receptor stimulation in the dermal papilla and melanocytes
Prolongs the anagen (growth) phase and increases melanogenesis, increasing follicle thickness, length, and darkness
Frames bimatoprost as a noninvasive, FDA-approved option for hypotrichosis
The eyelash growth-stimulatory agent in humans, bimatoprost, significantly extended the duration of anagen, resulting in more and longer eyelashes, but there was no evidence of follicle neogenesis.
Tauchi M, Fuchs TA, Kellenberger AJ, Woodward DF, Paus R, Lütjen-Drecoll E. · Br J Dermatol (2010)
Established a mouse eyelash model to study follicle biology and pharmacology
Bimatoprost significantly extended the anagen (growth) phase, producing more and longer eyelashes
Growth came from prolonged anagen, not new follicle formation — the preclinical basis for the clinical effect (and why it reverses)
Perioribital lipodystrophy is another well-documented outcome associated with chronic use of topical bimatoprost, which results in periorbital hallowing, upper eyelid sulcus deepening, eyelid retraction and enophthalmos.
Wang PX, Koh VT, Cheng JF. · Clin Ophthalmol (2014)